0.2996 0.014 (4.76%) | 11-03 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.48 | 1-year : | 0.56 |
Resists | First : | 0.41 | Second : | 0.48 |
Pivot price | 0.25 | |||
Supports | First : | 0.27 | Second : | 0.18 |
MAs | MA(5) : | 0.25 | MA(20) : | 0.26 |
MA(100) : | 0.42 | MA(250) : | 1.15 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 61.2 | D(3) : | 46.5 |
RSI | RSI(14): 51.6 | |||
52-week | High : | 5.59 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FREQ ] has closed below upper band by 7.1%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.32 - 0.32 | 0.32 - 0.32 |
Low: | 0.28 - 0.28 | 0.28 - 0.28 |
Close: | 0.3 - 0.3 | 0.3 - 0.3 |
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Thu, 16 Nov 2023
Cormorant Asset Management, LP Acquires New Stake in Frequency Therapeutics Inc - Yahoo Finance
Mon, 06 Nov 2023
Frequency Therapeutics Inc (FREQ) Announces Merger and Private Placement of $117 Million - GuruFocus.com
Mon, 06 Nov 2023
Frequency Therapeutics Inc (FREQ) Announces Merger and Private Placement of $117 Million - Yahoo Finance
Mon, 07 Aug 2023
Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger - Genetic Engineering & Biotechnology News
Fri, 14 Jul 2023
RNA-editing biotech aims to join Nasdaq via merger with Lexington company - Boston Business Journal - The Business Journals
Fri, 14 Jul 2023
Why Are Frequency Therapeutics Shares Surging Today - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 37 (M) |
Shares Float | 35 (M) |
Held by Insiders | 7.2 (%) |
Held by Institutions | 14.1 (%) |
Shares Short | 366 (K) |
Shares Short P.Month | 515 (K) |
EPS | -1.9 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -42.5 % |
Return on Equity (ttm) | -100 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -1.16 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.63 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -43 (M) |
Levered Free Cash Flow | -18 (M) |
PE Ratio | -0.16 |
PEG Ratio | 0 |
Price to Book value | 0.29 |
Price to Sales | 0 |
Price to Cash Flow | -0.26 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |